Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the
first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with
relapsed or refractory B-cell acute lymphoblastic leukemia.